Patents by Inventor Takao Hamakubo
Takao Hamakubo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110165179Abstract: To provide a therapeutic drug for Alzheimer's disease and/or a cancer. The therapeutic drug for Alzheimer's disease and/or a cancer contains an anti-nicastrin antibody, a derivative of the antibody, or a fragment of the antibody or the derivative.Type: ApplicationFiled: December 7, 2010Publication date: July 7, 2011Applicants: The University of Tokyo, Perseus Proteomics Inc.Inventors: Takeshi IWATSUBO, Tatsuhiko Kodama, Takao Hamakubo, Taisuke Tomita, Ikuo Hayashi, Yasuomi Urano, Hiroko Iwanari, Masao Ohkuchi
-
Patent number: 7955807Abstract: To provide a method of determining vasculopathy, which is a risk factor of myocardial infarction, angiopathic dementia, etc., at an early stage thereof (i.e., mild vasculopathy). The present invention provides a method of determining the severity of mild vasculopathy, including determining PTX3 level in an assay sample by use of an anti-PTX3 monoclonal antibody.Type: GrantFiled: November 10, 2006Date of Patent: June 7, 2011Assignees: The University of Tokyo, Perseus Proteomics Inc.Inventors: Tatsuhiko Kodama, Takao Hamakubo, Koji Maemura, Akira Sugiyama, Hiroko Iwanari, Isao Kohno, Yukio Ito
-
Patent number: 7875705Abstract: It is an object of the present invention to provide a novel antibody capable of specifically recognizing ROBO1 that is expressed in a cell membrane, a hybridoma that produces the above antibody, a method for producing the above antibody, and a tumor diagnostic agent used in PET comprising the above antibody. The present invention provides a monoclonal antibody capable of specifically recognizing ROBO1 existing on the surface of a cell, which is obtained by immunizing an animal to be immunized with a ROBO1-displaying budded baculovirus recovered from the culture supernatant of host cells infected with a recombinant baculovirus comprising the full-length cDNA of ROBO1 as an antigen.Type: GrantFiled: November 28, 2007Date of Patent: January 25, 2011Assignees: The University of Tokyo, Perseus Proteomics Inc.Inventors: Hiroko Iwanari, Isao Kohno, Takao Hamakubo, Yoshitaka Kumakura, Hirotaka Itoh, Toshiko Sakihama, Hiroyuki Aburatani, Toshimitsu Momose
-
Publication number: 20100247539Abstract: The present inventors discovered that the PepT-binding antibodies have the ability to inhibit the transport activity of peptide transporters, as a result of dedicated research. These antibodies may be utilized as cell growth inhibitors, for example, for treating and preventing cancer.Type: ApplicationFiled: February 25, 2010Publication date: September 30, 2010Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Tatsuhiko Kodama, Takao Hamakubo, Ryoichi Saitoh, Yoshiki Yamada
-
Publication number: 20100221766Abstract: A nuclear transfer promoter for Cdc42 protein comprising an isoprenoid synthesis inhibitor and/or a geranylgeranyl transferase inhibitor such as an HMG-CoA synthase inhibitor, an HMG-CoA reductase inhibitor, an AMPK activator or a farnesyl pyrophosphoric acid synthase preparation; utilization thereof; a method therefor; a blood vessel remedy comprising the nuclear transfer promoter for Cdc42 protein as the active ingredient; and a method of screening a blood vessel remedy which comprises assaying the ability of Cdc42 protein to transfer into nucleus.Type: ApplicationFiled: August 26, 2009Publication date: September 2, 2010Applicants: KOWA COMPANY, LTD., NISSAN CHEMICAL INDUSTRIES, LTD.Inventors: Takahide KOHRO, Yoshikazu SHIBASAKI, Takao HAMAKUBO, Tatsuhiko KODAMA
-
Patent number: 7731960Abstract: The present inventors discovered that the PepT-binding antibodies have the ability to inhibit the transport activity of peptide transporters, as a result of dedicated research. These antibodies may be utilized as cell growth inhibitors, for example, for treating and preventing cancer.Type: GrantFiled: March 26, 2004Date of Patent: June 8, 2010Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tatsuhiko Kodama, Takao Hamakubo, Ryoichi Saitoh, Yoshiki Yamada
-
Publication number: 20100093010Abstract: It is intended to provide an inhibitor for the formation of a ?-secretase complex which comprises a cholesterol synthesis inhibitor or a protein geranylgeranylation regulator as the active ingredient; and use of a cholesterol synthesis inhibitor or a protein geranylgeranylation regulator for producing the same. It is also intended to provide a method of screening a substance having an effect of inhibiting the formation of an active complex of ?-secretase which comprises assaying the activity of inhibiting cholesterol synthesis or quantifying cholesterol accumulated in lipid rafts in cells. It is also intended to provide a method of screening a cholesterol synthesis inhibitor, a protein geranylgeranylation regulator or an HMG-CoA reductase inhibitor which comprises assaying the effect of inhibiting the formation of an active complex of ?-secretase.Type: ApplicationFiled: October 27, 2009Publication date: April 15, 2010Applicants: KOWA COMPANY, LTD., NISSAN CHEMICAL INDUSTRIES, LTD.Inventors: Yasuomi Urano, Takao Hamakubo, Tatsuhiko Kodama
-
Publication number: 20100062449Abstract: To provide a method of determining vasculopathy, which is a risk factor of myocardial infarction, angiopathic dementia, etc., at an early stage thereof (i.e., mild vasculopathy). The present invention provides a method of determining the severity of mild vasculopathy, including determining PTX3 level in an assay sample by use of an anti-PTX3 monoclonal antibody.Type: ApplicationFiled: November 10, 2006Publication date: March 11, 2010Applicants: The University of Tokyo, Perseus Proteomics Inc.Inventors: Tatsuhiko Kodama, Takao Hamakubo, Koji Maemura, Akira Sugiyama, Hiroko Iwanari, Isao Kohno, Yukio Ito
-
Patent number: 7666998Abstract: The present inventors extensively studied and found that an antibody binding to PepT has cytotoxic activity and inhibits cell growth. These results suggest that an antibody binding to PepT, particularly an antibody having a cytotoxic activity, can be used as a cell growth inhibitor, for example, in treating and preventing cancer.Type: GrantFiled: December 4, 2002Date of Patent: February 23, 2010Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tatsuhiko Kodama, Takao Hamakubo, Ryoichi Saitoh, Iwao Ohizumi
-
Publication number: 20100041167Abstract: The present invention is directed to a method for diagnosing large intestinal cancer and/or polyp and a method for observing postoperative course or monitoring recurrence thereof, wherein each method includes detecting cystatin SN protein by use of an anti-cystatin SN antibody. The present invention is able to provide a kit for assaying cystatin SN, which can be used, in a simple manner, in a diagnosis performed prior to conventional barium enema examination and endoscopic examination which impose burdens on patients; as an indicator of metastasis and recurrence; and in the evaluation of therapeutic effects. The present invention provides a method for diagnosing or monitoring large intestinal cancer and/or polyp which can be performed in a simple manner, and thus can allow to design a new regimen rapidly.Type: ApplicationFiled: December 14, 2005Publication date: February 18, 2010Applicants: Perseus Proteomics Inc., The University of TokyoInventors: Hiroyuki Aburatani, Takahiro Shimamura, Kiyotaka Watanabe, Takeharu Asano, Shin Ohnishi, Takao Hamakubo, Akira Sugiyama, Naoki Hosomi, Hiroko Iwanari, Keisuke Ishii
-
Publication number: 20090092544Abstract: It is an object of the present invention to provide a novel antibody capable of specifically recognizing ROBO1 that is expressed in a cell membrane, a hybridoma that produces the above antibody, a method for producing the above antibody, and a tumor diagnostic agent used in PET comprising the above antibody. The present invention provides a monoclonal antibody capable of specifically recognizing ROBO1 existing on the surface of a cell, which is obtained by immunizing an animal to be immunized with a ROBO1-displaying budded baculovirus recovered from the culture supernatant of host cells infected with a recombinant baculovirus comprising the full-length cDNA of ROBO1 as an antigen.Type: ApplicationFiled: November 28, 2007Publication date: April 9, 2009Applicants: THE UNIVERSITY OF TOKYO, PERSEUS PROTEOMICS INC.Inventors: Hiroko Iwanari, Isao Kohno, Takao Hamakubo, Yoshitaka Kumakura, Hirotaka Itoh, Toshiko Sakihama, Hiroyuki Aburatani, Toshimitsu Momose
-
Publication number: 20080161348Abstract: A method for suppressing expression of PTX3 gene, which comprises administering an effective amount of a compound, which is represented by the following formula (1): wherein R1 represents an organic group, X represents —CH2CH2— or —CH?CH—, and R2 represents a hydrogen atom or an alkyl group, or a lactone derivative thereof, or a salt thereof. According to the present invention, a PTX3 gene expression suppressing method useful for the treatment of autoimmune diseases, especially rheumatoid arthritis can be provided.Type: ApplicationFiled: March 30, 2007Publication date: July 3, 2008Applicants: KOWA CO., LTD., Nissan Chemical Industries, Ltd.Inventors: Shigeru MORIKAWA, Akashi Izumi, Takao Hamakubo, Tatsuhiko Kodama
-
Patent number: 7329509Abstract: The object of the present invention is to develop a technique for expressing a functional membrane-bound protein by using baculovirus and insect cell expression system. The present invention provides a method for expressing a functional membrane-bound receptor protein which comprises steps of culturing a host infected with at least one type of recombinant baculovirus which contains a gene encoding an interacting protein and a gene encoding a membrane-bound receptor protein which interacts with said interacting protein to perform its function, and co-expressing said interacting protein and said membrane-bound receptor protein in a budded baculovirus released from said host.Type: GrantFiled: June 13, 2002Date of Patent: February 12, 2008Assignee: Toudai TLO, Ltd.Inventors: Takao Hamakubo, Tatsuhiko Kodama, Hiroshi Itoh, Kazuyuki Masuda
-
Publication number: 20070293535Abstract: A nuclear transfer promoter for Cdc42 protein comprising an isoprenoid synthesis inhibitor and/or a geranylgeranyl transferase inhibitor such as an HMG-CoA synthase inhibitor, an HMG-CoA reductase inhibitor, an AMPK activator or a farnesyl pyrophosphoric acid synthase preparation; utilization thereof; a method therefor; a blood vessel remedy comprising the nuclear transfer promoter for Cdc42 protein as the active ingredient; and a method of screening a blood vessel remedy which comprises assaying the ability of Cdc42 protein to transfer into nucleus.Type: ApplicationFiled: February 24, 2005Publication date: December 20, 2007Applicants: KOWA COMPANY, LTD., NISSAN CHEMICAL INDUSTRIES, LTD.Inventors: Takahide Kohro, Yoshikazu Shibasaki, Takao Hamakubo, Tatsuhiko Kodama
-
Publication number: 20070287146Abstract: The object of the present invention is to develop a technique for expressing a functional membrane-bound protein by using baculovirus and insect cell expression system. The present invention provides a method for expressing a functional membrane-bound receptor protein which comprises steps of culturing a host infected with at least one type of recombinant baculovirus which contains a gene encoding an interacting protein and a gene encoding a membrane-bound receptor protein which interacts with said interacting protein to perform its function, and co-expressing said interacting protein and said membrane-bound receptor protein in a budded baculovirus released from said host.Type: ApplicationFiled: June 13, 2002Publication date: December 13, 2007Applicant: CENTER FOR ADVANCED SCIENCE AND TECHNOLOGY INCUBATION, LTD.Inventors: Takao Hamakubo, Tatsuhiko Kodama, Hiroshi Itoh, Kazuyuki Masuda
-
Publication number: 20070281967Abstract: A nuclear transfer promoter for Rac protein comprising an isoprenoid synthesis inhibitor and/or a geranylgeranyl transferase inhibitor such as an HMG-CoA synthase inhibitor, an HMG-CoA reductase inhibitor, an AMPK activator or a farnesyl pyrophosphoric acid synthase preparation; utilization thereof; a method therefor; a blood vessel remedy comprising the nuclear transfer promoter for Rac protein as the active ingredient; and a method of screening a blood vessel remedy which comprises assaying the ability of Rac protein to transfer into nucleus.Type: ApplicationFiled: February 24, 2005Publication date: December 6, 2007Applicant: NISSAN CHEMICAL INDUSTRIES, LTD.Inventors: Takahide Kohro, Yoshikazu Shibasaki, Takao Hamakubo, Tatsuhiko Kodama
-
Publication number: 20070161700Abstract: It is intended to provide an inhibitor for the formation of a ?-secretase complex which comprises a cholesterol synthesis inhibitor or a protein geranylgeranylation regulator as the active ingredient; and use of a cholesterol synthesis inhibitor or a protein geranylgeranylation regulator for producing the same. It is also intended to provide a method of screening a substance having an effect of inhibiting the formation of an active complex of ?-secretase which comprises assaying the activity of inhibiting cholesterol synthesis or quantifying cholesterol accumulated in lipid rafts in cells. It is also intended to provide a method of screening a cholesterol synthesis inhibitor, a protein geranylgeranylation regulator or an HMG-CoA reductase inhibitor which comprises assaying the effect of inhibiting the formation of an active complex of ?-secretase.Type: ApplicationFiled: December 28, 2004Publication date: July 12, 2007Applicants: KOWA COMPANY, LTD., NISSAN CHEMICAL INDUSTRIES, LTD.Inventors: Yasuomi Urano, Takao Hamakubo, Tatsuhiko Kodama
-
Publication number: 20060210569Abstract: The present inventors discovered that the PepT-binding antibodies have the ability to inhibit the transport activity of peptide transporters, as a result of dedicated research. These antibodies may be utilized as cell growth inhibitors, for example, for treating and preventing cancer.Type: ApplicationFiled: March 26, 2004Publication date: September 21, 2006Inventors: Tatsuhiko Kodama, Takao Hamakubo, Ryoichi Saitoh, Yoshiki Yamada
-
Patent number: 7070978Abstract: Method for efficiently expressing a protein in an active form by using baculovirus expression system wherein the protein is selected from a membrane-bound enzyme, a substrate of the membrane-bound enzyme, a membrane-bound enzyme activator, a membrane-bound transport protein, a channel protein, a membrane structural protein, a protein involved in adhesion, a protein involved in antigen presentation, or a protein involved in formation of high dimensional structure of a protein. There is provided a method for expressing such a protein by culturing a host infected with at least one type of recombinant baculovirus which contains a gene encoding the protein, wherein the protein is expressed in a budded baculovirus released from the host.Type: GrantFiled: June 20, 2001Date of Patent: July 4, 2006Assignee: Toudai TLO, Ltd.Inventors: Takao Hamakubo, Tatsuhiko Kodama, Mineko Yamaguchi
-
Publication number: 20050281825Abstract: The present inventors extensively studied and found that an antibody binding to PepT has cytotoxic activity and inhibits cell growth. These results suggest that an antibody binding to PepT, particularly an antibody having a cytotoxic activity, can be used as a cell growth inhibitor, for example, in treating and preventing cancer.Type: ApplicationFiled: December 4, 2002Publication date: December 22, 2005Inventors: Tatsuhiko Kodama, Takao Hamakubo, Ryoichi Saitoh, Iwao Ohizumi